IL-32 and premature aging in people living with HIV
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.
['FUNDING_R01'] · CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (UNIVERSITY OF MONTREAL HOSPITAL) · NIH-11094103
This work explores whether a blood protein called IL‑32 is linked to early aging problems like heart disease, weak bones, and frailty in people living with HIV.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (UNIVERSITY OF MONTREAL HOSPITAL) (nih funded) |
| Locations | 1 site (MONTREAL, CANADA) |
| Trial ID | NIH-11094103 on ClinicalTrials.gov |
What this research studies
If you have HIV, researchers will combine heart imaging, blood tests, and lab experiments to look at levels and effects of the inflammatory protein IL‑32. They will measure IL‑32 from people who have information on frailty, body composition, and bone density, and link those measures to cardiovascular imaging findings. Lab studies will test how IL‑32 might affect cells and bone or blood-vessel processes that relate to aging. Results aim to clarify whether IL‑32 could help identify who is at higher risk for age-related complications and point to possible ways to lower that risk.
Who could benefit from this research
Good fit: Adults living with HIV, especially those experiencing or at risk for cardiovascular disease, low bone density, changes in body composition, or frailty, would be the ideal candidates.
Not a fit: People without HIV or those without concerns about aging-related conditions like heart disease, low bone density, or frailty are unlikely to benefit directly from this research.
Why it matters
Potential benefit: If successful, the work could help identify a blood marker that flags higher risk for early aging problems in people with HIV and suggest new targets to reduce that risk.
How similar studies have performed: Previous studies have suggested links between IL‑32 and inflammation, heart disease, and aging in HIV, but using IL‑32 as a marker or target across multiple aging traits is still relatively new.
Where this research is happening
MONTREAL, CANADA
- CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (UNIVERSITY OF MONTREAL HOSPITAL) — MONTREAL, CANADA (ACTIVE)
Researchers
- Principal investigator: TREMBLAY, CECILE — CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (UNIVERSITY OF MONTREAL HOSPITAL)
- Study coordinator: TREMBLAY, CECILE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus